Literature DB >> 15625704

Indomethacin preserves muscle mass and reduces levels of E3 ligases and TNF receptor type 1 in the gastrocnemius muscle of tumor-bearing mice.

Andrew Hitt1, Erin Graves, Donna O McCarthy.   

Abstract

Tumor-induced skeletal muscle wasting involves tumor necrosis factor (TNF) and the ubiquitin-proteasome pathway of muscle protein degradation. In this study, growth of the colon-26 adenocarcinoma in mice was associated with diminished gastrocnemius muscle mass and increased muscle levels of actin, ubiquitin-conjugated proteins, free ubiquitin, E3 ubiquitin ligases, and the type 1 TNF receptor (TNFR1). Indomethacin at 1 or 5 mg/kg/day reduced tumor growth and muscle levels of TNFR1. However, only the 5 mg dose of indomethacin reduced muscle wasting and muscle levels of the E3 ligases and actin. These data suggest that the beneficial effects of indomethacin in the treatment of tumor-induced skeletal muscle wasting may involve inhibition of TNF- and ubiquitin-mediated pathways of muscle protein degradation. These data also demonstrate that E3 ligases, which are involved in disuse atrophy, also are associated with tumor-induced skeletal muscle wasting. (c) 2004 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15625704     DOI: 10.1002/nur.20057

Source DB:  PubMed          Journal:  Res Nurs Health        ISSN: 0160-6891            Impact factor:   2.228


  5 in total

1.  Myocardial dysfunction in an animal model of cancer cachexia.

Authors:  Hui Xu; Danielle Crawford; Kirk R Hutchinson; Dane J Youtz; Pamela A Lucchesi; Markus Velten; Donna O McCarthy; Loren E Wold
Journal:  Life Sci       Date:  2010-12-14       Impact factor: 5.037

2.  Ibuprofen ameliorates fatigue- and depressive-like behavior in tumor-bearing mice.

Authors:  Diana M Norden; Donna O McCarthy; Sabahattin Bicer; Raymond D Devine; Peter J Reiser; Jonathan P Godbout; Loren E Wold
Journal:  Life Sci       Date:  2015-10-20       Impact factor: 5.037

3.  Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy.

Authors:  Alejandro Schcolnik-Cabrera; Alma Chavez-Blanco; Guadalupe Dominguez-Gomez; Mandy Juarez; Ariana Vargas-Castillo; Rafael Isaac Ponce-Toledo; Donna Lai; Sheng Hua; Armando R Tovar; Nimbe Torres; Delia Perez-Montiel; Jose Diaz-Chavez; Alfonso Duenas-Gonzalez
Journal:  Sci Rep       Date:  2021-03-04       Impact factor: 4.379

Review 4.  Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans?

Authors:  Tara C Mueller; Jeannine Bachmann; Olga Prokopchuk; Helmut Friess; Marc E Martignoni
Journal:  BMC Cancer       Date:  2016-02-08       Impact factor: 4.430

Review 5.  The Janus-Faced Role of Antioxidants in Cancer Cachexia: New Insights on the Established Concepts.

Authors:  Mohamad Assi; Amélie Rébillard
Journal:  Oxid Med Cell Longev       Date:  2016-08-24       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.